Company

UroGen Pharma Ltd.

UroGen Pharma develops and sells therapeutics for urological cancers, including FDA-approved ZUSDURI and Jelmyto.

About

Founded in 2004 in Princeton, US, UroGen Pharma develops and commercializes therapies for urological cancers, mainly non-muscle invasive bladder cancer. Its products include ZUSDURI™ (mitomycin) and Jelmyto®. Liz Barrett is CEO. In March 2022 the company completed a PIPE round raising USD 60.00 mn. Its revenue for fiscal 2024 was USD 90.40 mn.

2Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in